Safety Shot (NASDAQ: SHOT) is a pioneering force in the beverage landscape, introducing a groundbreaking solution designed to swiftly alleviate the effects of alcohol consumption. With its patented formula, Safety Shot accelerates the detoxification process, offering consumers a rapid path to relief and reshaping nocturnal revelries and morning recoveries. By leveraging a carefully crafted blend of scientifically proven ingredients, including vitamins, minerals and nootropics, Safety Shot enhances metabolic pathways responsible for breaking down blood alcohol levels, setting a new standard in post-alcohol consumption care.

In addition, the company today announced its strategic expansion to the Northeast regions of the United States. According to the update, the launch marks a significant milestone in the company’s rapid growth trajectory, with a primary focus in expanding a brand presence in key markets including New York City, Long Island and the Hamptons. “This expansion represents a significant opportunity for Safety Shot as we continue to broaden our reach and impact,” said Safety Shot’s Chief Revenue Officer Josh Wagner. “Establishing our presence in these key markets ahead of the summer kick off puts us in a position to capture brand recognition during a surge of heightened demand. We’re excited to introduce Safety Shot to the Northeast and pave the way for long-term success and growth in the region.”

To view the full press releases, visit https://ibn.fm/OmK7N and https://ibn.fm/5EO4O

About Safety Shot Inc.

Safety Shot, a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN